BNIP3 Antibody (YA4221)

BNIP3 (BCL2/adenovirus E1B 19 kDa-interacting protein 3) is a hypoxia-responsive mitochondrial protein within the BH3-only-like subgroup of the BCL2 family that regulates both programmed cell death and selective autophagy, making it a central mediator of cellular stress adaptation^[1][2]. Mechanistically, BNIP3 is transcriptionally induced by HIF-1α under hypoxic conditions and promotes mitochondrial quality control through mitophagy by facilitating the clearance of damaged mitochondria and limiting reactive oxygen species accumulation^[3][4][5]. Through this HIF-1α/BNIP3 signaling axis, BNIP3 coordinates mitochondrial turnover, apoptosis regulation, and metabolic adaptation in hypoxic tissues and tumor microenvironments^[3][5][6]. In disease models, BNIP3-mediated mitophagy has been linked to protection against ischemia-reperfusion injury in renal tubular cells through suppression of oxidative stress and apoptosis, while dysregulated BNIP3 expression has also been associated with cancer progression, cardiac dysfunction, and hypoxia-associated tissue injury^[5][1][7]. Compared with the related isoform BNIP3L/NIX, which is required for erythroid mitochondrial clearance, BNIP3 is more prominently associated with hypoxia-driven mitophagy and mitochondrial stress responses in multiple cell types^[1][8]. Experimental studies further demonstrate that BNIP3 can trigger either mitophagy or cell death depending on cellular context, highlighting its utility as a mechanistic target for investigating mitochondrial quality control, hypoxia signaling, and stress-induced cellular remodeling^[2][6][9].